MedTrace Logo

Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

NCT05557162 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20143

Last updated 2026-02-17

No results posted yet for this study

Summary

The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).

Conditions

  • Cardiac Amyloidosis

Interventions

OTHER

AI ECG Amyloid algorithm

Artificial intelligence enabled electrocardiogram screening tool used to identify the predictive model that best differentiates those at greatest risk for an amyloidosis diagnosis

Sponsors & Collaborators

Principal Investigators

  • Angela Dispenzieri, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2025-07-23
Completion
2025-07-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05557162 on ClinicalTrials.gov